Slide 1: Transforming Nerve Repair Through Science
For personal use only ASX:RNV Transforming Nerve Repair Through Science Quarterly investor update | May 2025
Slide 2: Important Notice & Disclaimer
Important Notice & Disclaimer Nature of Document: This presentation has been prepared and issued by ReNerve Ltd (Company) to provide general information about the Company. The information in this document is in summary form and should not be relied upon as a complete and accurate representation of a
Slide 3: Executive Summary
Executive Summary Development of Novel Nerve Repair & Regeneration Products For personal use only ReNerve is focused on developing a portfolio of products for the nerve repair and regeneration markets, with clearly defined commercial demand. Significant Product Portfolio ReNerve currently has one pr
Slide 4: Global Nerve Repair Biomaterial Market
Global Nerve $8.0Bn Global Nerve Repair Biomaterial Market Global Market by Segment Repair $6.0Bn 32% 16% Biomaterial For personal use only $4.0Bn Market USD $Bn $2.0Bn 52% - Nerve Wrap 2024 2025 2026 2027 2028 2029 2030 2031 Nerve Conduit North America Europe Nerve Grafts USD$1.69Bn ~900k Nerve Com
Slide 5: ReNerve's Opportunity
ReNerve’s Opportunity Nerve Cuff Nerve Conduit Nerve Guide Matrix Bionic Nerve For personal use only • Used on damaged or transected • Improved Nerve Cuff developed from • An ‘off-the-shelf’, ready to use nerve • An ‘off-the-shelf’, continuous nerve Product nerves with no gaps or gap closure scCO2 t
Slide 6: Company quarterly highlights
Company quarterly highlights Sales Highlights ReNerve Global Expansion & Distribution For personal use only United States Middle East Sales for Q3 FY25 of A$75K Established sales presence in target states with a focus on key hospital systems in each region. Entered into exclusive partnership with Un
Slide 7: NervAlign Nerve Cuff
For personal use only NervAlign® Nerve Cuff 01
Slide 8: NervAlign Nerve Cuff Key Features and Clinical Use
Key Features Clinical Use Patient Results Product For personal use only • Majority of cases to date have been focused on hand and wrist. • The NervAlign® Nerve Cuff is an FDA cleared product • Clinical cases have: used on damaged or transected nerves with no gaps or gap closure achieved by flexion.
Slide 9: Clinical Study
Clinical Study • ReNerve has completed an initial clinical study to explore the benefits For personal use only of using the NervAlign® Nerve Cuff in the repair of injured nerves. • The data will be presented late March at the American College of Foot and Ankle Surgeons conference in Phoenix. • Clini
Slide 10: Clinical Validation
Clinical Validation Clinical Study on the NervAlign® Nerve Cuff Comparison of Patient Pre & Post For personal use only At the American College of Foot and Ankle Surgeons Conference (27–30 March 2025), Surgery Pain Score ReNerve presented a comparative clinical study showing statistically significant
Slide 11: Clinical Use
Clinical Use For personal use only NervAlign® Damaged nerve Completed repair Removed gap filled Nerve Cuff used removed from held in place with with a conduit to protect the cuff the right thumb micro clips conduit implant
Slide 12: NervAlign Conduit
For personal use only 02 Conduit NervAlign®
Slide 13: Key Features
Key Features • ReNerve is focused on developing a conduit from scCO2 For personal use only tissue from the Nerve Cuff. • Project remains on track and working through commercial manufacturing • ReNerve will be able to leverage existing data from the Nerve Cuff FDA application to accelerate FDA approv
Slide 14: NervAlign Nerve Guide Matrix (Graft)
For personal use only NervAlign® Nerve Guide Matrix (Graft) 03
Slide 15: Key Features
Key Features & Guide Matrix For personal use only Product • The NervAlign® Neve Guide Matrix is an ‘off-the-shelf’, ready to use nerve graft replacement with internal guidance infrastructure. • ReNerve is developing three product options: ‒ Initial ‘wet’ prep nerve graft; ‒ Dry version that's hydrat
Slide 16: Near Term Milestones - 2025
Near Term Milestones - 2025 1H 2025 2H 2025 Near Term For personal use only NervAlign® Nerve Conduit into Market 27 February 2025 Progression of the Nerve (Q4 2025/Q1 2026) Partnership Signed for Mexico Market Guide Matrix to Stage 3 of Development 7 March 2025 Initial Clinical Cases for the R&D Tax
Slide 17: Investment Highlights
Investment Highlights For personal use only In Market Product Immediate Market Need Growing Market Nerve Cuff transitioned from R&D to Product offering promotes nerve injury Nerve repair biomaterials market is commercial sales post FDA market clearance, recovery and regrowth leading to faster foreca
Slide 18: Contact
For personal use only ASX:RNV Contact ReNerve Limited +61 (03) 9482 3940 info@renerve.com.au Level 10/99 Queen St, Melbourne, Victoria 3000 Australia
Slide 19: Board & Management
Board & Management For personal use only STEPHEN COOPER DR JULIAN CHICK DR MICHAEL PANACCIO DR DAVID RHODES DR ALEX ADAMIDES CHAIRMAN CEO & MANAGING DIRECTOR NON-EXECUTIVE DIRECTOR EXECUTIVE DIRECTOR & CSO CHIEF MEDICAL OFFICER Stephen was previously Managing Dr Julian Chick is an experienced Dr Mic